TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

To access the free health screening, people only need to register through the SATUSEHAT Mobile (SSM) application. Following ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Advertisement "AI-based software significantly improved detection of ultrasounds that were suspicious for congenital heart ... folks battling chronic kidney disease, new research shows.

Please contact us in case of abuse. In case of abuse, An explosive article has been published in the December issue of Proceedings on Chronic Diseases with Fatal Outcomes, the prestigious monthly ...